Kiniksa Pharmaceuticals International, plcKNSA
Market cap
$6.1B
P/E ratio
| 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Stock-based compensation | 6 | 15 | 21 | 25 | 25 | 27 | 31 |
| Cash from operations | -81 | -158 | -137 | -126 | 6 | 13 | 26 |
| Capital expenditures | -5 | -3 | -0 | -0 | -0 | -0 | -0 |
| Cash from investing | -239 | 49 | -23 | 129 | -8 | -30 | 38 |
| Cash from financing | 347 | 84 | 227 | 6 | 3 | 1 | 12 |
| Free cash flow | |||||||
| FCF margin (%) | - | - | - |